Literature DB >> 34903316

Extended-release Buprenorphine, an FDAindexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats (Rattus norvegicus).

Eden D Alamaw1, Benjamin D Franco1, Katechan Jampachaisri2, Monika K Huss1, Cholawat Pacharinsak1.   

Abstract

A new extended-release buprenorphine (XR), an FDA-indexed analgesic, has recently become available to the laboratory animal community. However, the effectiveness and dosing of XR has not been extensively evaluated for rats. We investigated XR's effectiveness in attenuating postoperative hypersensitivity in a rat incisional pain model. We hypothesized that high dose of XR would attenuate mechanical and thermal hypersensitivity more effectively than the low dose of XR in this model. We performed 2 experiments. In experiment 1, male adult Sprague-Dawley rats (n = 31) were randomly assigned to 1 of the 4 treatment groups: 1) saline (saline, 0.9% NaCl, 5 mL/kg, SC, once); 2) sustained-release buprenorphine (Bup-SR; 1.2 mg/kg, SC, once), 3) low-dose extended-release buprenorphine (XR-Lo; 0.65 mg/kg, SC, once), and 4) high-dose extended-release buprenorphine (XR-Hi; 1.3 mg/kg, SC, once). After drug administration, a 1 cm skin incision was made on the plantar hind paw under anesthesia. Mechanical and thermal hypersensitivity were evaluated 1 d before surgery (D-1), 4 h after surgery (D0), and for 3 d after surgery (D1, D2, and D3). In experiment 2, plasma buprenorphine concentration (n = 39) was measured at D0, D1, D2, and D3. Clinical observations were recorded daily, and a gross necropsy was performed on D3. Mechanical and thermal hypersensitivity were measured for 3 d (D0-D3) in the saline group. Bup-SR, XR-Lo, and XR-Hi effectively attenuated mechanical hypersensitivity for D0-D3. Plasma buprenorphine concentrations remained above 1 ng/mL on D0 and D1 in all treatment groups. No abnormal clinical signs were noted, but injection site reactions were evident in the Bup-SR (71%), XR-Lo (75%), and XR-Hi (87%) groups. This study indicates that XR-Hi did not attenuate hypersensitivity more effectively than did XR-Lo in this model. XR 0.65 mg/kg is recommended to attenuate postoperative mechanical hypersensitivity for up to 72 h in rats in an incisional pain model.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34903316      PMCID: PMC8786384          DOI: 10.30802/AALAS-JAALAS-21-000081

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.706


  35 in total

1.  The role of drug-lipid interactions on the disposition of liposome-formulated opioid analgesics in vitro and in vivo.

Authors:  C R Bethune; C M Bernards; T Bui-Nguyen; D D Shen; R J Ho
Journal:  Anesth Analg       Date:  2001-10       Impact factor: 5.108

Review 2.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

3.  Evaluation of an improved sustained-release buprenorphine formulation for use in mice.

Authors:  Jason R Healy; Jennifer L Tonkin; Stacey R Kamarec; Mitchell A Saludes; Sherif Y Ibrahim; Rae R Matsumoto; Jeffrey H Wimsatt
Journal:  Am J Vet Res       Date:  2014-07       Impact factor: 1.156

4.  Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research.

Authors:  Dinesh Kumar Mishra; Vinod Dhote; Punit Bhatnagar; Pradyumna Kumar Mishra
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

5.  Use of Liposomal Bupivacaine for Postoperative Analgesia in an Incisional Pain Model in Rats (Rattus norvegicus).

Authors:  Stacey C Kang; Katechan Jampachaisri; Travis L Seymour; Stephen A Felt; Cholawat Pacharinsak
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-01-01       Impact factor: 1.232

6.  Cardiovascular effects of buprenorphine in anesthetized dogs.

Authors:  E A Martinez; S M Hartsfield; L D Melendez; N S Matthews; M R Slater
Journal:  Am J Vet Res       Date:  1997-11       Impact factor: 1.156

7.  The animal pharmacology of buprenorphine, an oripavine analgesic agent.

Authors:  A Cowan; J C Doxey; E J Harry
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

8.  Correlation between body weight changes and postoperative pain in rats treated with meloxicam or buprenorphine.

Authors:  Matthew P Brennan; Albert J Sinusas; Tamas L Horvath; J G Collins; Martha J Harding
Journal:  Lab Anim (NY)       Date:  2009-03       Impact factor: 12.625

9.  Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice.

Authors:  Tannia S Clark; David D Clark; Robert F Hoyt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

10.  Opioid depression of respiration in neonatal rats.

Authors:  J J Greer; J E Carter; Z al-Zubaidy
Journal:  J Physiol       Date:  1995-06-15       Impact factor: 5.182

View more
  3 in total

1.  Pharmacokinetics of Sustained-release and Extended-release Buprenorphine in Mice after Surgical Catheterization.

Authors:  Marissa Saenz; Elizabeth A Bloom-Saldana; Tim Synold; Richard W Ermel; Patrick T Fueger; James B Finlay
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-08-25       Impact factor: 1.706

2.  Efficacy of 3 Buprenorphine Formulations for the Attenuation of Hypersensitivity after Plantar Incision in Immunodeficient NSG Mice.

Authors:  Justin D Arthur; Eden D Alamaw; Katechan Jampachairsri; Patrick Sharp; Claude Nagamine; Monika K Huss; Cholawat Pacharinsak
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-09-06       Impact factor: 1.706

3.  Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats.

Authors:  Mingyun Zhang; Eden Alamaw; Katechan Jampachaisri; Monika Huss; Cholawat Pacharinsak
Journal:  PLoS One       Date:  2022-10-17       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.